Skip to content
★ Sign in to follow
에스

에스엘테라퓨틱스 Stock: price and insider trades · South Korea

No insider purchase over the last 90 days. The latest, by LB인베스트먼트, was filed 06 Jul 2023.

에스엘테라퓨틱스: what insiders have been doing

에스엘테라퓨틱스 belongs to the Health Care sector. Filings by its managers are published through DART (FSS). The past year has been quiet: not a single insider filing for 에스엘테라퓨틱스. The previous disclosure was published on 27 June 2024.

Other companies in the same sector with recent insider buying flagged by our signals: Relmada Therapeutics, Inc. and MAIA Biotechnology, Inc. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.

Insider Decl.
12
Thresholds
n/a
Buy Volume
n/a
3 ops. · all time
Sell Volume
n/a
8 ops. · all time

Financial data

· cache

Last declaration on 27 June 2024
Declarations12 total
  • ▼
    Related company / holdingExecutives
    0DART
    ShareKRXDART:20240627000203
  • ▼
    Executives
    0DART
    123,677 sharesKRXDART:20231018000042
  • ▼
    Executives
    0DART
    168,649 sharesKRXDART:20230810000194
  • ▼
    Executives
    0DART
    168,649 sharesKRXDART:20230809000513
  • ▲
    Executives
    0DART
    395,000 sharesKRXDART:20230706000039
    Canonical exit: 3 Oct 2023 (T+90)
  • ▼
    Executives(filed)
    0DART
    199,110 sharesKRXDART:20221227000548
  • ▼
    Related company / holdingExecutives(filed)
    0DART
    ShareKRXDART:20221227000606
  • ▼
    Related company / holdingExecutives(filed)
    0DART
    ShareKRXDART:20221227000574
  • ▲
    Executives(filed)
    0DART
    1,089,474 sharesKRXDART:20221021000083
    Canonical exit: 19 Jan 2023 (T+90)
  • ▼
    Related company / holdingExecutives(filed)
    0DART
    ShareKRXDART:20221021000081
  • ▲
    Executives(filed)
    0DART
    711,743 sharesKRXDART:20221020000252
    Canonical exit: 18 Jan 2023 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART

12 of 12 declarations

About 에스엘테라퓨틱스

Listed on the XKRX market, 에스엘테라퓨틱스 is a company in the health and pharmaceutical sector. It focuses on developing innovative therapeutic solutions.